Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0N3QF
|
|||
| Former ID |
DIB001802
|
|||
| Drug Name |
AZD-5122
|
|||
| Indication | Chronic obstructive pulmonary disease [ICD-11: CA22; ICD-10: J44, J44.9] | Phase 1 | [1] | |
| Company |
AstraZeneca plc
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | C-X-C chemokine receptor type 2 (CXCR2) | Target Info | Modulator | [2] |
| KEGG Pathway | Cytokine-cytokine receptor interaction | |||
| Chemokine signaling pathway | ||||
| Endocytosis | ||||
| Epithelial cell signaling in Helicobacter pylori infection | ||||
| NetPath Pathway | TNFalpha Signaling Pathway | |||
| Panther Pathway | Inflammation mediated by chemokine and cytokine signaling pathway | |||
| Interleukin signaling pathway | ||||
| Pathway Interaction Database | IL8- and CXCR2-mediated signaling events | |||
| Reactome | Chemokine receptors bind chemokines | |||
| G alpha (i) signalling events | ||||
| WikiPathways | GPCRs, Class A Rhodopsin-like | |||
| Peptide GPCRs | ||||
| GPCR ligand binding | ||||
| GPCR downstream signaling | ||||
| GPCRs, Other | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00984477) Study to Investigate the Activity of AZD5122 When Given as a Single Dose to Healthy Male Subjects. U.S. National Institutes of Health. | |||
| REF 2 | Molecular Approaches To Target GPCRs in Cancer Therapy. Pharmaceuticals 2011, 4(4), 567-589. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.